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Background/Objectives: With mucocutaneous candidiasis being highly prevalent in HIV 
patients, the emergence of fluconazole-resistant Candida species forms a major challenge 
in treating and eradicating these infections. The objective of this study was to establish 
the antifungal activity of K21, a membrane-rupturing antimicrobial compound derived from 
a silica quaternary ammonium compound (SiQAC) with tetraethoxysilane (TEOS).
Methods: The study sample included 81 Candida species of which 9 were type strains 
and 72 were clinical isolates. Minimum inhibitory concentrations, synergy, fractional 
inhibitory concentration index (FICI), and time kill assays were determined by broth 
microdilution. Electron microscopy (EM) was used to determine the qualitative changes 
brought about after treatment with K21.
Results: K21 inhibited the growth of all fluconazole-resistant and susceptible Candida 
strains with only 2 h of exposure required to effectively kill 99.9% of the inoculum, and a 
definite synergistic effect was observed with a combination of K21 and fluconazole. EM 
demonstrated the presence of two forms of extracellular vesicles indicative of biofilm 
formation and cell lysis.
Conclusion: The study established the efficacy of K21 as an antifungal agent and with 
fluconazole-resistant candidiasis on the increase, the development of K21 can provide a 
promising alternative to combat acquired drug resistance.
Keywords: HIV-associated candidiasis, antimicrobial compounds, Candida, fluconazole, antifungal susceptibility, 
broth microdilution
INTRODUCTION
The oral cavity may show the first signs and symptoms of HIV infection (Hirata, 2015), with 
the progression of HIV infection leading to frequent and recurrent episodes of highly severe 
oropharyngeal candidiasis (OPC) and systemic fungemia (Junqueira et  al., 2012), often caused 
by fluconazole-resistant non-albicans Candida species (Mulu et  al., 2013).
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Currently, five main classes of antifungal agents exist, each 
with its own particular cellular target and mode of action (Liu 
et al., 2014). The triazoles (Fluconazole, Itraconazole, Voriconazole, 
Posaconazole and Isavuconazole) and allylamines (Naftifine and 
Terbinafine) inhibit synthesis of ergosterols by C14-demethylase 
and squalene epoxidase activity, respectively. The echinocandins 
(Caspofungin, Micafungin and Anidulafungin) interfere with 
cell wall synthesis. Damage to the cell wall results in disrupted 
membranes and as a result of osmotic fragility, cytoplasmic 
contents are spilled, thereby suppressing further fungal growth. 
The fluropyrimidine, 5-fluorocytosine, inhibits nucleic acid 
synthesis, interfering with normal cell metabolism, protein 
synthesis, a complete destruction of the cell interior and collapse 
of the cell wall (Kim et  al., 2011).
The most commonly used antifungal agents in cases of 
HIV-associated OPC are azoles (Fluconazole, Itraconazole and 
Ketoconazole) and polyenes (Amphotericin B) (Patil et  al., 
2018). Although Fluconazole (FCZ) is reported to be  the drug 
of choice (Sholapurkar et al., 2009), the improper and extensive 
use of the azoles has led to the emergence of fluconazole-
resistant Candida and an increased occurrence of non-albicans 
Candida species, causing refractory mucosal candidiasis in HIV 
patients with advanced immunosuppression (Witaningrum et al., 
2018), resulting in increased morbidity and mortality (Sardi 
et  al., 2013; Africa and Abrantes, 2017). Non-albicans Candida 
species such as Candida glabrata are reported to show a higher 
rate of FCZ resistance (11–13%) followed by Candida tropicalis 
(4–9%), and Candida parapsilosis (2–6%) (Cleveland et  al., 
2012; Pfaller et al., 2015). Being fungistatic rather than fungicidal, 
FCZ has been implicated in both inherent and acquired resistance 
(Berkow and Lockhart, 2017).
The Centres for Disease Control and Prevention (CDC, 
2014) revealed an alarming 7% increase in fluconazole-resistant 
Candida species, creating the need for the development of 
new antifungals which demonstrate both an increase in drug 
potency and improved tolerability, particularly in patients who 
are frequently affected by resistant Candida species. The toxicity 
of the polyenes, the inadequate oral absorption of the 
echinocandins, combined with the fungistatic activity and 
resistance to azoles, necessitates a change in treatment options.
Quaternary ammonium compounds (QAC) are nitrogen 
containing compounds with a N (nitrogen) atom attached to 
four different covalent bonds (Jiao et al., 2017). They are highly 
potent in combating antimicrobial resistance and the critical 
need for the development of new and effective antimicrobial 
drugs incorporating QAC is imperative in the fight against 
resistant species (Jennings et  al., 2015; Jiao et  al., 2017). K21 
is an antimicrobial compound developed by Dr. Kirk Kimmerling 
in 2011 (Ablashi, 2015). The process of hydrolysis and 
condensation of a silica quaternary ammonium compound 
(SiQAC) with tetraethoxysilane (TEOS) resulted in the production 
of a 3-dimensional antimicrobial macromolecule with multiple 
arms of membrane rupturing potential (Prusty et  al., 2014). 
Depending on the form of the SiQAC starting material, either 
methanol (if methacryloxy), or ethanol (if ethacryloxy) SiQAC, 
is generated as a by-product. The ethacryloxy SiQAC-derived 
K21 is preferred for materials being placed in the oral cavity 
and has been reported to exhibit an inhibitory effect on the 
growth of Porphyromonas gingivalis, Escherichia coli, Streptococcus 
mutans, Actinomyces naeslundii and Enterococcus faecalis (Gong 
et al., 2012a,b, 2014) along with the development of K21-coated 
sutures which may offer the potential of reducing post-operative 
infection and bacteremia (Meghil et  al., 2015). The positive 
charges on K21 act by drawing the negatively charged microbe 
toward the material, while the long 18 carbon chain tails pierce 
the cell walls causing lysis. The use of K21 as an antiviral 
against HSV-1, HHV-6A, and HHV-7 has also been reported 
(Gulve et al., 2016), but to our knowledge, its antifungal activity 
has not been investigated.
The present study aimed to evaluate K21 as an effective 
antifungal agent against resistant Candida species by establishing 
the time required by the compound to inhibit the growth of 
Candida species and demonstrating synergy between K21 and FCZ.
MATERIALS AND METHODS
Candida Isolates Used in This Study
Candida type strains were obtained from the American 
Type Culture Collections (ATCC, Manassas, VA) and National 
Collection of Pathogenic Fungi (NCPF, Public Health 
Culture Collections, England) and included Candida albicans 
(ATCC 90028 and NCPF 3281), Candida krusei (ATCC 2159), 
C. glabrata (ATCC 26512), Candida dubliniensis (NCPF 3949a), 
C. tropicalis (ATCC 950), C. parapsilosis (ATCC 22019), Candida 
lusitaniae (ATCC 34449), and Candida kefyr (ATCC 4135). 
These served as quality controls in the K21 antifungal susceptibility 
assays and checkerboard synergy and time kill assays.
Once the activity of K21 on the type strains was established, 
its activity was further tested on a selection of fluconazole-
resistant (n  =  62) and -susceptible (n  =  10) HIV-associated 
oral Candida species previously isolated (Abrantes et  al., 2014) 
and stored with consent at −80°C in Pro-Lab Microbank 
microbial preservation vials (Cat. no. PL.170/M, Pro-Lab, 
Canada). This was an in vitro study of stored species for which 
ethical clearance was granted by the Biomedical Research 
Committee of the University of the Western Cape. The stored 
isolates were revived by growth in 10  ml Sabouraud dextrose 
broth (Cat. no. CMO147, Oxoid, UK) and incubation at 37°C 
for 3–5  days. Purity of growth was confirmed by streaking 
broth cultures onto solid Sabouraud dextrose agar (Cat. no. 
84088, Sigma-Aldrich, USA) and incubating at 37°C for 24–48 h.
Preparation of K21
A solution of K21 in 50% ethanol was obtained from KHG fiteBac 
Technology (USA). Stock solutions were prepared by dissolving 
the compound in acetone and then in sterile distilled water, with 
resulting concentrations ranging from 0.98 to 249.9  μg/ml.
Antifungal Susceptibility Assays
Minimum inhibitory concentration values of FCZ against nine 
Candida strains were determined by broth microdilution 
according to the Clinical and Laboratory Standards Institute 
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M27A3 approved standard protocol (Clinical and Laboratory 
Standards Institute, 2008). Fresh colonies of Candida from 
Sabouraud dextrose agar were suspended in sterile saline 
solution (0.85% NaCl) and the cell density adjusted to a 0.5 
McFarland standard, yielding a yeast stock suspension of 
1.5  ×  106  CFU/ml. The working suspension was prepared by 
making a 1:50 dilution of the stock suspension followed by 
a 1:20 dilution with Roswell Park Memorial Institute (RPMI) 
1640 medium (Cat. no. R6504, Sigma-Aldrich, USA) buffered 
with MOPS (N-Morpholino-propanesulfonic acid) 0.165  M 
adjusted to pH  7.0, resulting in an inoculum concentration 
of 1  ×  103–5  ×  103  CFU/ml. The FCZ (Cat. no. 8929, Sigma-
Aldrich, USA) drug concentration ranged from 0.12–256 μg/ml 
with sensitivity to FCZ indicated by CLSI approved breakpoint 
MIC values of ≤8  μg/ml, intermediate or dose-dependent 
susceptibility MIC between 16 and 32  μg/ml and resistance 
MIC ≥64  μg/ml (Eraso et  al., 2008).
Disk diffusion assays were not performed in the present 
study due to the inability of K21 to diffuse into the agar media.
The microdilution test for K21 was performed in 96-well 
microtiter plates containing 100  μl of 2-fold serial dilutions 
of K21 in 100 μl RPMI medium. The plates were then inoculated 
with 100  μl of the inoculum and incubated for 24  h at 37°C. 
The MIC value readings were recorded both visually and 
spectrophotometrically using an Anthos 2010 spectrophotometer 
(Biochrom, UK) at 450 nm (Schwalbe et al., 2007; Wong et al., 
2014). MICs were defined as the lowest concentration of K21 
inhibiting visible growth or 100% of the microorganism. Based 
on CLSI criteria, 100% growth inhibition was observed as 
clear wells in the plates. The positive control included 100  μl 
of 25  μg/ml of FCZ in 50  μl inoculum, while 100  μl inoculum 
without K21 served as the negative control. Antimicrobial 
activity was confirmed by the lack of growth after transferring 
10  μl of the sample from the clear wells onto Sabouraud 
dextrose agar and incubating at 37°C for 24  h.
The readings were also interpreted by adding 40  μl 
iodonitrotetrazolium chloride (INT) dye (Cat. no. 18377, Sigma-
Aldrich, USA) into the wells and incubating for a further 2  h. 
The MIC values were read by the change in color. The 
concentration range of K21 was 0.98–249.9  μg/ml.
Antimicrobial Synergism
Synergism between K21 and FCZ was determined using the 
nine type strains and the CLSI M27A2 and CLSI M27A3 
microdilution checkerboard techniques (Clinical and Laboratory 
Standards Institute, 2002; Clinical and Laboratory Standards 
Institute, 2008). A starting inoculum was prepared by inoculating 
a tube of saline with fresh colonies of Candida and adjusting 
to a 0.5 McFarland standard (1.5  ×  106  CFU/ml of yeasts). 
A 1:10 dilution was done by adding 1  ml aliquot of inoculum 
to 9 ml RPMI yielding a working inoculum of 1.5 × 105 CFU/ml. 
Broth microdilutions involving 2-fold serial dilutions were 
performed with K21 alone and FCZ alone and double 
concentrations of K21 and FCZ in combination so that serial 
dilutions contained various concentrations of the combinations 
of K21 and FCZ. The concentration range of K21 was 
0.49–249.9 μg/ml and for FCZ, it was 0.12–64 μg/ml. A positive 
growth control containing inoculum without K21 and FCZ was 
included for each isolate and the negative control consisted of 
RPMI alone. The plates were incubated at 37°C for 24  h and 
inhibition of growth was confirmed by recording the turbidity 
and by the addition of 40  μl INT dye. The MIC values for 
K21, FCZ and the K21/FCZ combinations were observed.
To assess the interactions of the drug combination, the data 
obtained by visual reading were further analyzed using the 
fractional inhibitory concentration index (FICI) using the 
formula FICI = FICA + FICB where:
 FICA = MIC of drug A in combination
MIC of drug A alone
 FICB = MIC of drug B in combination
MIC of drug B alone
FICI values were interpreted as follows: FICI ≤0.5 = Synergy; >0.5 
to ≤4  =  Indifference; >4  =  Antagonism (Johnson et  al., 2004).
Time-Kill Assay
A time-kill assay was conducted to assess the rate of fungicidal 
activity of K21 against FCZ-susceptible C. albicans (ATCC 
90028) and FCZ-resistant C. glabrata (ATCC 26512). The study 
was performed by a method previously described and evaluated 
by Klepser et  al. (1998). Broth microdilution was performed 
with a starting inoculum of 1–5 × 105 CFU/ml and K21 was 
tested at concentrations equal to MIC, ½ MIC, and ¼ MIC 
obtained by the microdilution checkerboard method. Plates 
were incubated at 37°C for 24  h prior to removing a sample 
for the determination of colony counts at predetermined time 
points of 0, 2, 4, 6, 8, 12, and 24  h. A 40  μl sample was 
streaked onto sterile SDA plates. Colony counts were performed 
using a Gallenkamp 20/CX-300 colony counter (Gallenkamp 
Co. Ltd., UK). K21 was considered to have fungicidal activity 
when there was a reduction in microbial growth of ≥3log10 
decrease in colony count after 24  h, resulting in about 99.9% 
reduction in CFU/ml relative to the initial inoculum. Fungistatic 
activity was considered as a reduction in growth lower than 
99.9% or  <  3log10 in CFU/ml from the initial inoculum after 
24  h (Locke et  al., 2018).
In addition, C. albicans (ATCC 90028 and NCPF 3281), 
C. glabrata (ATCC 26512) and C. dubliniensis (NCPF 3949a) 
were tested for synergism by the time kill study. The microtiter 
plates were challenged with K21 and fluconazole alone and 
with K21 and fluconazole in a 1:1 combination at their final 
concentrations of ½ MIC and ¼ MIC.
“Synergy” was defined as ≥2 log reduction in colony count 
for a given combination compared to the colony count obtained 
with the most active single agent and “Antagonism” was defined 
as ≥2 log increase in colony count for a given combination 
compared to the colony count obtained with the most active 
single agent (Zusman et  al., 2013), while a  >2 log and <2 log 
log increase or decrease in colony count at 24  h with the 
combination compared with that of the most active single agent 
alone was reported as “indifference” (Johnson et  al., 2004).
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ELECTRON MICROSCOPY (EM)
Scanning  Electron Microscopy (SEM)
A volume of 200  μl of samples from microdilution wells of 
K21 (½ MIC 31.24  μl), FCZ (½ MIC 8  μl), and K21  +  FCZ 
(½ MIC 15.62  +  4  μl, respectively) were prepared for EM 
after treatment with K21 at 2, 4, 6, and 24  h. Untreated 
C. albicans served as the control.
The cells were harvested by centrifugation at 5,000  rpm for 
10  min to obtain a pellet. After discarding the supernatant, the 
pellets were washed three times for 5 min each with 0.1 M phosphate 
buffered saline (PBS) pH  7.4, fixed with 2.5% glutaraldehyde 
(Cat. no. G5882, Sigma-Aldrich, USA), washed thrice in PBS for 
30  min, followed by two washes of 5  min each in distilled water. 
Cells were dehydrated in graded ethanols (50, 70, 90, and 100%), 
followed by critical point drying, sputter coated with gold–palladium 
for 60  s (Quorum Q15OTES system) and observed in a Zeiss 
Auriga field emission scanning electron microscope at 5  kV.
Transmission Electron Microscopy (TEM)
Samples from ½ MIC wells treated with K21 were harvested by 
centrifugation at 5,000  rpm for 10  min to obtain the fungal 
pellet. After discarding the supernatant, pellets were washed with 
0.1  M PBS (pH  7.4) three times for 5  min each, the supernatant 
was discarded and pellets were fixed in Karnovsky solution (4 ml 
10% formaldehyde +0.2  ml of 25% glutaraldehyde) in 1  ml 
10x PBS, followed by washing first in PBS twice for 5  min each, 
then in distilled water before discarding the final supernatant. 
Cells were then fixed in 4% low melting agarose solution and 
immediately transferred to 4°C or ice for 30  min to solidify the 
agarose. The solidified pellets were cut into small sections and 
washed in PBS for 5  min. After 2 washes in distilled water, cells 
were dehydrated in graded ethanols (30, 50, 70, 90 and 95%) 
twice for 10  min each in 100% ethanol for 5  min each, followed 
by embedding in a mixture of LR White  (Cat. no. L9774, Sigma-
Aldrich, USA) and ethanol in proportions of 50:50, 25:75 and 
finally, 100% LR White. Ultrathin sections (80 nm) were collected 
on nickel grids and stained with 2% uranyl acetate (AGR1260A, 
Agar Scientific, UK) and lead citrate for 5  min each. Grids were 
examined using a Tecnai 20 transmission electron microscope 
operating at 200 kV at magnification between 8,000× and 34,000×.
Statistical Analyses
Data was analyzed using SPSS software programme (SPSS 
Version 24; SPSS Inc, Chicago, IL, USA) and were expressed 
as the mean (standard deviation) of at least three independent 
experiments. Student’s paired t-test was employed to compare 
K21 and FCZ results. p  ≤  0.05 indicated significance.
RESULTS
Comparison of the Antimicrobial Activity 
of FCZ and K21 on Their Own and in 
Combination
Figure 1 demonstrates the broth microdilution test in a 96 
well microtiter plate. The clear wells in the plate indicate the 
minimum inhibitory concentration (MIC) of K21. The presence 
of viable cell growth appeared turbid and was enhanced by 
the addition of INT dye.
Table 1 shows the susceptibility of the nine type strains. 
When treated with FCZ alone, C. albicans (ATCC 90028 and 
NCPF 3281) showed MIC values of 16 and 32 μg/ml, respectively, 
while C. krusei (ATCC 2159) and C. glabrata (ATCC 26512) 
both showed an MIC value of 64  μg/ml. The MIC values for 
C. dubliniensis (NCPF 3949a) and C. tropicalis (ATCC 950) 
were 2 and 1 μg/ml, respectively, while the MIC for C. parapsilosis 
(ATCC 22019) was 2  μg/ml and C. lusitaniae (ATCC 34449) 
and C. kefyr (ATCC 4135) were both 1  μg/ml.
For K21, all the type strains, except C. lusitaniae (ATCC 34449) 
and C. kefyr (ATCC 4135) exhibited a MIC of 62.48  μg/ml.
Table 1 shows that K21 enhanced the effect of FCZ, while 
in the last five species listed, there was a major drop in MIC 
when K21 and FCZ were combined, compared to their individual 
MICs. A synergistic effect was observed in C. dubliniensis (NCPF 
3949a), C. tropicalis (ATCC 950) and C. lusitaniae (ATCC 34449). 
Indifference was observed with C. albicans (ATCC 90028 and 
NCPF 3281), C. parapsilosis (ATCC 22019), C. kefyr (ATCC 4135), 
C. glabrata (ATCC 26512), and C. krusei (ATCC 2159). The MIC 
values of K21 alone showed higher concentrations compared to 
those of FCZ. There was no antagonistic effect found in the study.
Figure 2 demonstrates synergistic activity of K21 and FCZ 
on C. dubliniensis (NCPF 3949a) in the checkerboard 
microdilution assay.
Time-Kill Assays of K21 on Its Own and in 
Combination With FCZ
The strains that exhibited synergy and indifference with the 
FICI indices were subjected to the time kill study, 
using ½ MIC and ¼ MIC combinations.
FIGURE 1 | Broth microdilution assay for K21. Media control shows no 
growth (Row A, wells 11 and 12); Positive control show growth (Row B,  
wells 11 and 12); Negative control shows no growth (Row C, wells 11 and 12); 
Solvent control shows growth (Row D, wells 11 and 12).
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The time required by K21 to inhibit the growth of Candida 
was determined and since no growth occurred at MIC, 
C. albicans (ATCC 90028) was used as a susceptible control, 
along with ½ MIC and ¼ MIC concentrations of K21. 
Figure  3A shows the time kill curve plotted against 
C. albicans vs. different concentrations of K21. Analysis of 
the graph showed a steady growth curve for C. albicans 
reaching a plateau at around 10  h. The MIC concentration 
showed a reduction in fungal growth at 2  h (≥3log10 of 
CFU/ml or lower than 99.9% reduction in microbial growth 
of the initial inoculum) which continued for 24  h. The ½ 
MIC showed a rapid growth curve up to 6  h with slower 
growth continuing up to 24  h. A similar curve was obtained 
for ¼ MIC.
Both K21 and FCZ tested at concentrations of ½ MIC 
and ¼ MIC combinations showed a reduction of C. albicans 
(ATCC 90028) from 4  h till 8  h (Figure 3B). There was a 
2log10 of CFU/ml reduction in the growth in ½ MIC combinations 
of K21 and FCZ compared with killing by the most active 
single agent. At ¼ MIC combinations, a 2.5log10 difference 
was observed compared to both K21 and FCZ alone.
Analysis of the graph (Figure 4A) shows a steady growth 
curve for the FCZ-negative control C. glabrata up to 6  h after 
which it plateaued. The ½ MIC and ¼ MIC presented a growth 
peak up to 6  h of exposure showing a fungistatic activity 
with a reduction in microbial growth of ≤3log10 of CFU/ml 
or lower than 99.9% of the initial inoculum. At 2  h, the MIC 
showed fungicidal activity with a reduction ≥3log10 of CFU/ml 
or about 99.9% reduction in microbial growth relative to the 
initial inoculum. In both the Candida strains tested, no viable 
cells were detected after 24  h indicating the fungicidal effect 
of K21.
Figure 4B demonstrates the time kill graph plotted against 
FCZ-resistant C. glabrata (ATCC 26512). There was a steady 
reduction in the growth of the cells till 12  h. A 4.5log10 
difference at ½ MIC combinations was shown when compared 
to the single agent and a 5.5log10 difference to the starting 
inoculum. However, at ¼ MIC combinations, a < 2log10 reduction 
in the cell growth was observed. There was no synergy exhibited 
at ¼ MIC combinations of K21 and FCZ.
Figure 5A shows C. albicans (NCPF 3281) at ¼ MIC 
concentrations of K21 and FCZ combinations with a reduction 
of cell growth seen at 8  h and an increase in cell growth at 
12 h, continuing till 24 h. At ½ MIC combinations, growth reduced 
at 4  h with growth increasing from 12 to 24  h. There was an 
approximate 2.8log10 difference and 2.5log10 difference in the viable 
cell counts at ½ MIC and ¼ MIC combinations respectively, 
compared with the cells treated with either K21 or FCZ alone.
C. dubliniensis (NCPF 3949a) exhibited a 4.5log10 difference 
at both ½ MIC and ¼ MIC combinations of the drugs to 
their single drug concentration (Figure 5B). At ½ MIC 
combinations, there was a reduction in the viable count at 
4  h, which remained constant till 12  h and reduced at 24  h. 
A reduction in viable cells was observed at ¼ MIC combinations 
at 8  h, remaining so at 12 and 24  h.
The antimicrobial effect of K21 was then tested against 
HIV-associated Candida isolates, of which 91.9% were C. albicans, 
6.5% were C. glabrata, and 1.6% were C. dubliniensis. FCZ results 
TABLE 1 | Microdilution checkerboard method to determine K21/FCZ synergy using Candida type strains.
Species Individual MICs Combination MICs ΣFICI Interpretation
FIC A FIC B
Candida K21 MIC (μg/ml) FCZ MIC (μg/ml) K21 MIC (μg/ml) FCZ MIC (μg/ml)
C. albicans ATCC 90028 62.48 16 31.24 8 1 Indifference
C. albicans NCPF 3281 62.48 32 62.48 16 1.5 Indifference
C. krusei ATCC 2159 62.48 64 62.48 16 1.25 Indifference
C. glabrata ATCC 26512 62.48 64 62.48 16 1.25 Indifference
C. dubliniensis NCPF 3949a 62.48 2 1.95 0.5 0.28 Synergy
C. tropicalis ATCC 950 62.48 1 0.97 0.25 0.26 Synergy
C. parapsilosis ATCC 22019 62.48 2 3.9 1 0.56 Indifference
C. lusitaniae ATCC 34449 124.95 1 0.97 0.25 0.25 Synergy
C. kefyr ATCC 4135 124.95 1 1.95 0.5 0.51 Indifference
≤0.5 = synergy, >0.5 to ≤4 = indifference (Johnson et al., 2004).
FIGURE 2 | Checkerboard broth microdilution assay for K21 and FCZ 
synergy of C. dubliniensis (NCPF 3949a). K21 (Rows A and B); Fluconazole 
(Rows C and D); Combination of K21 and FCZ (Rows E and F); Positive 
control (Row A, well 12); Negative control (Row B, well 12).
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showed that among the FCZ-susceptible strains (Table 2), a 
MIC range of 0.12–1  μg/ml was observed for C. albicans with 
a MIC50 of 0.5  μg/ml. The MIC range for C. dubliniensis was 
0.03–0.5  μg/ml with a MIC50 of 0.5  μg/ml demonstrated for 
both C. dubliniensis and C. glabrata. On treatment with K21, 
the MIC ranged between 31.24 and 62.48  μg/ml for C. albicans 
with MIC50 values of 62.48  μg/ml recorded for C. albicans and 
C. dubliniensis and 31.24  μg/ml recorded for C. glabrata.
Among the FCZ-resistant /intermediate strains, the mean 
MIC for C. albicans, C. glabrata and C. dubliniensis were 232.07, 
24.00 and 256  μg/ml, respectively (Table 2).
The MIC ranges for K21 with C. albicans and C. glabrata 
were 31.24–124.95 and 31.24–62.48  μg/ml, respectively with a 
MIC50 of 62.48 μg/ml, compared to a higher MIC of 124.95 μg/ml 
for C. dubliniensis (Table 3).
The difference between the resistant and susceptible Candida 
clinical isolates when exposed to FCZ and K21 was significantly 
different (Table 3).
Having established the quantitative action of K21, 
we proceeded to examine the qualitative changes to C. albicans 
only, using electron microscopy.
SEM
Untreated C. albicans cells (Figure 6A), appeared smooth, 
with polar buds, and budding into two daughter cells was 
also observed. After 2  h exposure to K21 (Figure 6B), cells 
A
B
FIGURE 3 | Time kill curve showing the log10 of CFU/ml versus time of FCZ-susceptible C. albicans (ATCC 90028) when exposed to various concentrations of  
K21 alone (A) and K21 + FCZ (B).
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appeared interconnected by thin threads (arrows), and although 
their surfaces appeared smooth, sparse white vesicles were 
observed on some cells. This became more pronounced after 
4 h (Figure 6C), with the white vesicles increasing significantly 
with bud scars randomly positioned on convoluted cell surfaces 
and not defined to the polar region of the cell only (Figure 6C). 
The distortion of cells became more pronounced after 6  h 
(Figure 6D), with total lysis of the cell observed after 
24  h (Figure 6E).
The same control used in Figure 6 applies to Figures 7 and 8 
since they were all prepared from the same microdilution plate. 
Cells treated with FCZ demonstrated shrinkage after treatment 
for 2  h (Figure 7A), with wrinkled cell surfaces. Bud scars 
were evident and sparse vesicles were observed on a few cells. 
The cells appeared cracked and desiccated after 4 h (Figure 7B), 
with multiple polar scars evident on some cells (arrow). This 
became more pronounced after 6  h (Figure 7C), where total 
distortion of cells, with multiple bud scars were observed. After 
24  h of exposure to FCZ, cells appeared cracked with broken 
cell walls and some cellular remnants with further evidence of 
multiple bud scars and extracellular vesicles (Figure 7D).
The K21  +  FCZ combination after 2  h exposure did not 
show the wrinkled cells when treated with FCZ on its own 
(Figure 8A). Several bud scars were apparent on the cells along 
with an increase in the white flocullar material (arrows). After 
4  h (Figure 8B), the cells were elongated with several showing 
A
B
FIGURE 4 | Time kill curve showing the log10 of CFU/ml versus time of FCZ-resistant C. glabrata (ATCC 26512) when exposed to various concentrations of K21  
(A) and K21 + FCZ (B).
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larger extracellular vesicles and debris on convoluted cell surfaces. 
This progressed over 6  h showing severely distorted and lysed 
cells with extracellular vesicles and deposits of white flocculent 
material (Figure 8C). After 24  h, masses of cellular remnants 
were observed along with distorted and lysed cells (Figure 8D) 
with no evidence of the fine flocculent material described earlier. 
Several damaged buds not limited to polar regions were evident 
and the cell surfaces were convoluted and lysed.
TEM
TEM analysis of untreated C. albicans cells (Figure 9A) 
showed a distinct cell wall and cell membrane with regular 
cellular contents (a), a well-defined nucleus with prominent 
nucleolus (b) and other intracellular organelles such as 
mitochondria (c). A few white vesicles were observed close 
to the nucleolus (d) and around the periphery of the cell 
membrane in some parts (e). A vacuole (f) and an electron 
dense body (g) were visible to the left of the nucleolus.
After 2  h (Figure 9B) of exposure to K21 (31.24  μg/ml), 
an amorphous mass of electron dense material was observed (a), 
the cell wall remained intact, while the cell membrane showed 
“blebs” along its periphery separating it from the cell wall (b). 
Formation of intracellular vesicles (c) and vacuoles (d) were 
apparent. The nucleus showed shrinkage (e), and a tiny vesicle 
with an electron dense center (f) was observed in proximity 
to the bleb formation along the cell membrane (g).
After 4  h, (Figure 9C) the lipid deposits increased (a) and 
several melanin granules were observed along the periphery 
of the cell membrane, along with thickening of the cell wall (b). 
Disruption of the cell membrane to initiate bleb formation 
A
B
FIGURE 5 | Time kill curve results of K21 and FCZ against (A) C. albicans (NCPF 3281) and (B) C. dubliniensis (NCPF 3949a).
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was evident (c) as well as vesicular compartments containing 
electron dense material (d). Many of these electron 
dense particles were scattered throughout the cell along with 
vacuoles (e).
After 6  h (Figure 9D), evidence of bleb initiation was 
observed where melanin deposits and other electron dense 
material appeared along the periphery of the disrupted cell 
membrane (a) with several other tiny electron dense deposits 
observed within the cell membrane and extracellularly (b). 
Lipid deposits increased (c) and melanin deposits were seen 
along the periphery of both the cell membrane and the cell 
wall in some parts of the cell (d). Chromatin condensation 
was evident along with a few vacuoles (e).
Following 24  h of exposure to K21, C. albicans showed 
pronounced shrinkage of the nucleus (a) with melanin deposited 
along the periphery of the cell membrane especially where blebs 
were starting to form (b). Vacuoles increased significantly (c), 
with general destruction of intracellular contents (Figure  9E). 
Another cell (Figure 9F), showed extensive vacuole formation 
after 24  h (a), with melanin deposits along the cell membrane 
(b). The cell wall and cell membrane had separated where blebs 
had formed (c) and were in the process of being released (d). 
Some cellular remnants with tiny electron dense material were 
observed extracellularly (e), with vesicles (f) and lipid forms (g) 
observed within a highly vacuolated and disorganized cytoplasm, 
along with invaginations of the cell wall and membrane (h).
DISCUSSION
Drug overuse and the inappropriate prescription of drugs may 
result in the mutation of organisms (Read and Woods, 2014), 
leading to the evolution of resistant microbes and associated 
complications (Lushniak, 2014). This has serious implications 
for the treatment of OPC, particularly in South Africa where 
Candida carriage was reported to be  higher than in other 
parts of the world (Patel et al., 2006), with the rate in HIV-positive 
subjects (83%) being significantly higher (p  <  0.001) than in 
HIV-negative subjects (63%).
The present study analyzed the antifungal activity of K21 
against nine Candida type strains, followed by the testing of 
randomly selected isolates from HIV infected patients using 
broth microdilution, a technique considered to be  the golden 
standard for antimicrobial susceptibility references.
Even though K21 was found to be  effective at higher 
concentrations compared to FCZ, in the present study, the 
action of K21 as an antifungal agent can be embraced. However, 
to inhibit the growth of the resistant C. albicans strains, FCZ 
exhibited a MIC50 of 256  μg/ml. Hence it can be  noted that 
K21 is effective against FCZ-resistant strains.
The time kill study is used to determine the fungicidal or 
fungistatic action of a drug or a compound and the relationship 
between the drug concentration and microbial activity over 
time and although time-consuming and expensive, it is widely 
used to determine the synergy of drug combinations 
(Shrestha et  al., 2015). In the present study, time kill assays 
for K21 with C. albicans (ATCC 90028 and NCPF 3281), 
C. dubliniensis (NCPF 3949a) and C. glabrata (ATCC 26512) 
were evaluated by the checkerboard method. Although the 
results gained by both methods were similar, C. glabrata (ATCC 
26512) demonstrated a synergistic interaction at ½ MIC when 
K21 and FCZ were combined. The indifferent interaction between 
K21/FCZ with C. krusei (ATCC 2159) and C. glabrata (ATCC 
26512) may be  due to the resistant mechanisms of the strains.
We elected to use only a susceptible C. albicans (ATCC 
90028) and resistant C. glabrata (ATCC 26512) to determine 
the rate of action of K21, because these are the predominant 
species responsible for causing widespread fungal infection in 
both healthy and immunocompromised patients (Leroy et  al., 
2009), with C. glabrata being extremely difficult to treat due 
to its high resistance to fluconazole. The current study showed 
that 2  h was required to kill 99.9% of both C. albicans and 
C. glabrata at a concentration of 62.48  μg/ml. The ½ MIC 
and ¼ MIC showed fungistatic activity with a growth peak 
up to 6 h indicating that K21 can be considered as an alternative 
to FCZ for the treatment of resistant strains.








Susceptible 0.46 (±0.25) 46.86 (±16.46) 8.87 9 0.000
Resistant 219.03 (±86.15) 62.98 (±29.11) −14.69 61 0.000
TABLE 2 | Effect of K21 on HIV-associated Candida clinical strains.
Candida n (%) Fluconazole (FCZ) K21
Mean MIC (SD) MIC range (μg/ml) MIC50 (μg/ml) Mean MIC (SD) MIC range (μg/ml) MIC50 (μg/ml)
FCZ-susceptible
C. albicans 6 (60%) 0.52 (±0.28) 0.12–1 0.5 46.86 (±17.11) 31.24–62.48 62.48
C. glabrata 2 (20.0%) 0.50 (±0.00) – 0.5 31.24 (±0.00) – 31.24
C. dubliniensis 2 (20.0%) 0.26 (±0.33) 0.03–0.5 0.5 62.48 (±0.00) – 62.48
FCZ-resistant/intermediate
C. albicans 57 (91.9%) 232.07 (±71.88) 4–256 256 63.02 (±28.61) 31.24–124.95 62.48
C. glabrata 4 (6.5%) 24.00 (±9.23) 16–32 16 46.86 (±18.03) 31.24–62.48 62.48
C. dubliniensis 1 (1.6%) 256 – – 124.95 – –
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The FICI indices showed definite synergy for C. dubliniensis 
(NCPF 3949a), C. tropicalis (ATCC 950) and C. lusitaniae 
(ATCC 34449). Low MIC values were observed at ΣFICI 
for all of the nine type strains. None of the combinations 
exhibited antagonism in the study. This suggests that 
K21 acts as a potent antifungal agent when combined 
with fluconazole.
Electron microscopy revealed the different events which 
occurred following treatment with K21 and we  propose that 
the extracellular vesicles observed after 2 h were distinctly different 
from those observed after 24  h. The vesicles observed initially, 
appear to be an indication that the cells were wanting to survive 
the effects of the antifungals by protecting themselves by forming 




FIGURE 6 | SEM of C. albicans (ATCC 90028) treated with K21 after 2, 4, 6 and 24 h. (A) untreated cells (Control) show smooth unattached cells except where 
budding into daughter cells occurred. Magnification = 5.00 kX. After 2 h (B), cells are joined by fine threads (yellow arrows), some showed budding and separation 
into two cells (green arrows). Others showed small extracellular vesicles (blue arrows). The cells were mostly smooth. Magnification = 5.00 kX. After 4 h (C), cells 
showed an increase in extracellular vesicles (green arrows) with bud scars not confined to the polar region (yellow arrows). Magnification = 10.00 kX. After 6 h (D), 
cells were distorted with convoluted surfaces (green arrow), increased extracellular vesicles (blue arrows) and disrupted budding (yellow arrows). Magnification = 20.00 
kX. After 24 h (E), cells were severely distorted (orange arrows) with flocculent deposits resembling a biofilm matrix (yellow arrows). Magnification = 10.00 kX.
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presence of melanin granules in and around the cell membrane 
after 4  h of exposure to K21  in TEM sections. These were 
similar to those reported by Walker et  al. (2010) after 3  days 
of exposure to 1 mM DOPA (3,4,dihydroxyphenylalanine-melanin). 
Melanins are biological compounds thought to represent an 
amorphous mixture of polymers exported from the fungal cells 
by means of the fusion of cell and vesicular membranes. Melanins 
are involved in a range of virulence properties including survival 
and resistance to antifungal agents (Nosanchuk and Casadevall, 
2003). It is not clear whether extracellular vesicles must cross 
the cell wall to be  released by the interaction with other cell 
wall components (Wolf et  al., 2014), whether it originates and 
is extruded from the cytoplasm and exported extracellularly 
(Eisenman et al., 2009), or comes about as a result of membrane 
budding and multivesicular bodies (Rodrigues et  al., 2013). The 
integrity of the cell membrane is vital to the survival of the 
fungal cell, providing a barrier to environmental stress. Thus 
many of the metabolic processes of the cell are to be  found 
there. Ergosterol is abundant in fungal cell membranes and plays 
an important role in regulating permeability and fluidity of the 
membrane as well as cell division (Hata et  al., 2010) and is an 
important target for most antifungals including Polyenes 
(Amphotericin B, deoxycholate, Liposomal lipid complex) which 
bind directly to ergosterol, thereby destroying the integrity of 
the cell membrane (Kim et  al., 2011). Vesicles are reported to 
be  composed of proteins, lipids, polysaccharides, pigments and 
nucleic acids with release from its cell of origin occurring as a 
result of the outward budding of the cell membrane (ectosomes) 
(Minciacchi et  al., 2015) or inward budding of the endosomal 
membrane forming multivesicular bodies which, upon fusion 
with the cell membrane release exosomes (Rodrigues et al., 2008; 
Oliveira et  al., 2010). Lastly, they can also be  referred to as 
apoptotic bodies released when cell membrane blebbing occurs 
during apoptosis. Vesicles containing melanin are sometimes 
rearranged by the alteration of cell wall components (Eisenman 
et  al., 2009) and C. albicans has been reported to transport 
RNA via its extracellular vesicles (Peres da Silva et  al., 2015).
Controversy exists regarding the nomenclature and 
size  distribution of the different types of EVs (Gould and 
Raposo, 2013), despite minimal criteria for their classification 
having been defined (Lötvall et  al., 2014) and thus, it is 
accepted that the term EV be  used until specific markers 
A B
C D
FIGURE 7 | SEM of C. albicans (ATCC 90028) treated with FCZ after 2, 4, 6 and 24 h. Untreated cells in previous figure served as the control for Figures 7 and  8 
as well. (A) Cell surfaces appear shrunken and wrinkled with sparse extracellular vesicles (yellow arrows) and bud scars (orange arrow). Magnification = 5.00 kX.  
(B) Desiccated cells with cracks (yellow arrow), multiple bud scars (orange arrows) and convoluted surfaces. Magnification = 10.00 kX. (C) Shrunken desiccated 
cells with some severely distorted (yellow arrow) and multiple bud scars (blue arrows). Magnification = 5.00 kX. (D) Cracked (yellow arrow) and lysed desiccated 
cells (blue arrow), some totally distorted (orange arrow) and others with polar buds (green arrows). Magnification = 10.00 kX.
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are able to classify them (Abels and Breakefield, 2016). 
Because of the discrepancies regarding the characterization 
of the different EVs, interpretation of data involving 
EVs  create  limitations  in  drawing accurate conclusions 
(Caruso  and  Poon, 2018).
The morphological changes observed by SEM and TEM 
in the present study are not unlike those observed in other 
studies which investigated the effect of other azoles and 
classes of antifungals. In vitro treatment of C. albicans with 
Miconazole (10−7  M) showed increases in buds as well as 
bud scars on several regions of the cell wall indicating that 
Miconazole interferes with the normal division of the yeast 
cells causing a single cell to make multiple attempts to divide 
and survive (De Nollin and Borgers, 1975). Because of the 
fungistatic activity of the drug, viable cells were not able 
to divide resulting in the formation of clusters of interconnected 
cells as observed after exposure for 2  h to both K21 as 
well as FCZ in the present study. When exposed to the 
minimal fungicidal dose (10−6  M) and fungicidal doses 
(10−4  M) of Miconazole, De Nollin and Borgers (1975) 
observed smooth cells coated with vesicles and because large 
amounts of fragmented cell walls were observed, they presumed 
that the vesicles were cytoplasmic components derived from 
broken cells. They also observed that cells which appeared 
normal by SEM, showed necrosis by TEM. TEM showed 
cytoplasmic membrane material limited to the cell membrane 
with a variety of intact cell walls. Thus they cautioned that 
it cannot be  taken for granted that a normal shape and 
size of cell need necessarily indicate viability, particularly 
since they found that the fungicidal dose brought about 
lytic changes while the cell wall was unaffected in part of 
the population. They also observed an accumulation of 
membranous material at sites of what appeared to 
be  bud formation.
Combination therapies increase efficacy thereby preventing 
drug resistance. Different approaches have identified effective 
combinations of natural compounds with marketed drugs 
(Prasad and Kapoor, 2005; Spitzer et  al., 2017). Mady et  al. 
(2018) demonstrated synergistic activity between Miconazole 
and urea for treating C. albicans. Other examples include the 
A B
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FIGURE 8 | SEM of C. albicans (ATCC 90028) treated with K21 + FCZ after 2, 4, 6, and 24 h. (A) Cells connected by appendages and appear to be separating 
(yellow arrow), multiple bud scars are evident, not limited to polar regions of cell (blue arrows), and an increase in flocculent deposits (green arrows). 
Magnification = 10.00 kX. (B) Severely distorted cells with larger extracellular vesicles (yellow arrows) and cracking (green arrow) Magnification = 10.00 kX. (C) 
Totally distorted and disintegrating cells (yellow arrows) with evidence of lytic cell remnants (green arrows). Magnification = 10.00 kX. (D) Severely disrupted cells 
(green arrow), masses of extracellular vesicles and cell remnants (yellow arrows). Magnification = 2.00 kX.
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FIGURE 9 | TEM of C. albicans (ATCC 90028) treated with K21. In the untreated cell (A) the cell wall and attached cell membrane enveloped the cytoplasm of the 
cell which contained cellular organelles (a), a well-defined nucleus with prominent nucleolus (b), mitochondria (c), tiny intracellular vesicles arranged close to the 
nucleolus (d), and around the periphery of some parts of the cell membrane (e). A vacuole (f) and an electron dense body were also observed (g). After 2 h (B), 
electron dense material appeared in an amorphous mass (a), the cell membrane showed “blebs” separating it from the cell wall (b) with intracellular vesicles (c) and 
vacuoles (d). The nucleus showed shrinkage (e) and a tiny vesicle with an electron dense center (f) could be seen near to the bleb forming along the cell membrane 
(g). After 4 h (C), the lipid deposits increased (a) and melanin granules were deposited along the periphery of the cell membrane (b). There was thickening of the cell 
wall and disruption of the cell membrane (c). Vesicular compartments contained electron dense material (d) and other electron dense vesicles were seen inside the 
cell membrane along with vacuoles (e). After 6 h (D), melanin deposits were seen along the periphery of the cell membrane (a), with several other larger electro 
dense vesicles observed outside of the cell wall as well as within the cell (b). We observed an increase in lipid deposits (c), melanin deposits (d) chromatin 
condensation and vacuoles (e). After 24 h (E), condensation of the nucleus (a), melanin deposits along the cell membrane along with changes in the membrane 
were seen (b), as well as vacuoles (c) and large vesicle forms (d). Another cell (F) after 24 h in K21, revealed vacuole formation (a), melanin deposits along the cell 
membrane (b), separation of the cell wall from the cell membrane where a bleb had formed (c), a vesicle being released (d) and extracellular remnants with electron 
dense inclusions (e). Other vesicle (f) and lipid forms (g) were also observed, along with invaginations of the cell wall and membrane (h).
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use of novel compounds such as APX001A and APX2020  in 
combination with FCZ with a FICI of 0.37 (Shaw et  al., 2018), 
calcium channel blockers such as amlodipine, nifedipine, 
bendipine, and flunarizine with FCZ with FICI <0.5 (Liu et al., 
2016), licofelone and FCZ (Liu et  al., 2017). Studies of the 
interaction between baicalein (a flavonoid isolated from the 
roots of Scutellaria baicalensis, a Chinese medicinal plant) and 
FCZ showed that the fungicidal activity of FCZ  +  baicalein 
was greater than that of each agent individually, thus 
demonstrating synergy between the two. SEM revealed that 
C. albicans, when exposed to baicalein alone, produced filamentous 
forms with flocculent extracellular material when combined with 
FCZ, suggestive of biofilm formation (Serpa et  al., 2012). 
We  observed several features consistent with their findings and 
others, which may suggest that for the first few h, the activity 
of K21 appeared to be fungistatic (as indicated by the microdilution 
and EM observations), followed by fungicidal activity.
Several forms of cell death have been proposed, all of 
which have been defined by morphological criteria 
(Kroemer et  al., 2009). In this study, we  have demonstrated 
different events leading to cell death. The presence of multiple 
buds, tiny vesicles and flocculent deposits suggest a desperate 
attempt at cell survival (autophagy) by budding and formation 
of a protective biofilm, followed by oncosis (as revealed by 
melanin deposits along the cell membranes, loss of cell 
membrane integrity with bleb formation) and finally, apoptosis 
(demonstrated by cell shrinkage and the production of 
extracellular apoptotic bodies and cell remnant deposits) 
(Kroemer et al., 2009; Weerasinghe and Buja, 2012). Previous 
studies reported apoptosis in C. albicans at low fungicidal 
doses of Amphotericin B and necrosis in high fungicidal 
doses (Phillips et  al., 2003), while Hao et  al. (2013) found 
that Caspofungin had a harmful effect on the cell wall 
without the cytoplasm being affected. They demonstrated 
chromatin margination and condensation along the nucleus, 
concluding that large black dots and blebs from the nucleus 
are indicative of apoptosis.
Apoptosis, a highly organized process leading to cell death 
and essential for normal growth and maintenance of cells, 
has also been demonstrated in C. albicans following treatment 
with purpurin, a neutral red anthraquinone pigment in 
Rubia tinctorum L, also known as madder root (Kang et  al., 
2010). Apoptosis is usually indicated by dysfunction of 
mitochondria (enlarged, containing electron dense deposits), 
which are organelles considered to be  the energy powerhouse 
of the cell and also playing an important role in cellular 
integrity (Wang and Youle, 2009), along with protein 
aggregation, chromatin condensation, increase in number and 
size of lipid droplets, vacuoles and cytoplasmic autolysis (Kang 
et  al., 2010), all of which have been observed in cells treated 
with K21  in this study.
Other studies using natural products and showing 
characteristics of apoptosis include Coprisin (peptide from dung 
beetle) (Lee et al., 2012) and ethanolic crude extracts of Punica 
granatum L (pomegranate) (Anibal et  al., 2013).
Since K21 alone or in combination with FCZ has proved 
its effectiveness against both FCZ- resistant and susceptible 
Candida isolates, it can be  considered that the above in vitro 
study renders the evolvement of the novel compound K21 as 
a possible alternative to fluconazole. Furthermore, a study by 
Daood et  al. (2017), reported the effectiveness of K21 as a 
dental cavity disinfectant, thus introducing its use in oral health 
care as an antimicrobial agent, while a cytotoxic study on K21 
found no major toxic effects on primary human fibroblasts 
(Gulve et  al., 2016), further indicating the competency in the 
application of the compound.
This study recognized the phenotypical differences between 
the type strains and clinical isolates in their antimicrobial 
susceptibility, thereby confirming the value of investigating 
clinical isolates along with type strains in the pathogenic 
potential and antifungal activity of Candida species 
(Silva et al., 2010). Laboratory adapted type strains may undergo 
micro-evolution during several in vitro subcultures since their 
first isolation, thus not suitably representing current clinical 
strains when it comes to drug susceptibility (Andes et al., 2004).
In the present study the antifungal activity of K21 against 
Candida type strains and fluconazole-resistant oral Candida 
species showed that K21 inhibited the growth of FCZ-resistant 
Candida at a faster rate, demonstrating a potent feature of 
the compound, thereby suggesting it be  considered for the 
development of a curative therapy for all forms of fungal 
diseases, particularly in HIV-associated opportunistic infections.
Limitations of this study include our failure to determine 
whether a similar in vitro efficacy with K21 could be observed 
with other drug classes besides the azoles and that we limited 
the electron microscopy to Candida albicans only. However, 
this study has set the stage for future studies to gain a 
better understanding of the mechanism of the antifungal 
activity of K21.
The need for the development of innovative antifungal 
agents with a rapid killing action is critical to prevent the 
spread of invasive fungal infections and the long-term use of 
antifungals, thereby reducing or preventing the emergence of 
resistant Candida species. K21, with its fast-acting fungicidal 
property may create a new chapter in the discovery of new 
antifungal agents.
AUTHOR CONTRIBUTIONS
CA conceptualized and coordinated the study, participated in 
its design and wrote the final manuscript. CJ performed the 
antimicrobial investigations, analyzed the data and prepared 
the first draft of the manuscript. PA characterized the Candida 
isolates and contributed to the editing of the manuscript. BP 
and DA contributed to the formulation of the protocol and 
editing of the manuscript. All authors read and approved the 
final manuscript.
FUNDING
This work was supported by KHG fiteBac Technology 
(grant no. TTOC1705-02).
John et al. K21, A Potent Antifungal Agent
Frontiers in Microbiology | www.frontiersin.org 15 May 2019 | Volume 10 | Article 1021
ACKNOWLEDGMENTS
The authors gratefully acknowledge Dr. Kirk Kimmerling from 
KHG fiteBac Technology, Marietta, GA 30064, USA, who 
developed and supplied the K21 and funded this study and 
Professor Gerhard Krueger, Department of Pathology and 
Laboratory Medicine, University of Texas- Houston Medical 
School, Houston, TX, United States for his guidance.
 
REFERENCES
Abels, E. R., and Breakefield, X. O. (2016). Introduction to extracellular vesicles: 
biogenesis, RNA cargo selection, content, release, and uptake. Cell. Mol. 
Neurobiol. 36, 301–312. doi: 10.1007/s10571-016-0366-z
Ablashi, D. (2015). The antimicrobial compound, K21, inhibits replication of 
enveloped and non-enveloped DNA and RNA viruses. 5th World Congress 
on Virology, Atlanta, GA.
Abrantes, P. M. D. S., McArthur, C. P., and Africa, C. W. J. (2014). Multi-drug 
resistant oral Candida species isolated from HIV-positive patients in South 
Africa and Cameroon. Diagn. Microbiol. Infect. Dis. 79, 222–227. doi: 10.1016/j.
diagmicrobio.2013.09.016
Africa, C. W. J., and Abrantes, P. M. D. S. (2017). Candida antifungal drug 
resistance in sub-Saharan African populations: a systematic review. F1000Res. 
5:2832. doi: 10.12688/f1000research.10327.2
Andes, D., Nett, J., Oschel, P., Albrecht, R., Marchillo, K., and Pitula, A. (2004). 
Development and characterization of an in  vivo central venous catheter 
Candida albicans biofilm model. Infect. Immun. 72, 6023–6031. doi: 10.1128/
IAI.72.10.6023-6031.2004
Anibal, P. C., Peixoto, I. T., Foglio, M. A., and Höfling, J. F. (2013). Antifungal 
activity of ethanolic extracts of Punica granatum L and evaluation of the morphological 
and structural modifications of its compounds upon the cells of Candida species. 
Braz. J. Microbial. 44, 839–848. doi: 10.1590/S1517-83822013005000060
Berkow, E. L., and Lockhart, S. R. (2017). Fluconazole resistance in Candida 
species: a current perspective. Infect. Drug Resist. 10, 237–245. doi: 10.2147/
IDR.S118892
Caruso, S., and Poon, K. H. (2018). Apoptotic cell-derived extracellular vesicles: 
more than just debris. Front. Immunol. 9:1486. doi: 10.3389/fimmu.2018.01486
Centers for Disease Control and Prevention–US Department of Health and Human 
Services. (2014). Antibiotic resistance threats in the United States, 2013. Available 
at: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf (Accessed 
August 18, 2018).
Cleveland, A. A., Farley, M. M., Harrison, L. H., Stein, B., Hollick, R., Lockhart, 
S. R., et al. (2012). Changes in incidence and antifungal drug resistance in 
candidemia: results from population-based laboratory surveillance in Atlanta and 
Baltimore, 2008–2011. Clin. Infect. Dis. 55, 1352–1361. doi: 10.1093/cid/cis697
Clinical and Laboratory Standards Institute [CLSI]. (2008). Reference method 
for broth dilution antifungal susceptibility testing of yeasts; approved standard. 
3rd Edn. CLSI document M27-A3. (Wayne, PA: Clinical and Laboratory 
Standards Institute [CLSI]).
Clinical and Laboratory Standards Institute/National Committee for Clinical 
Laboratory Standards. (2002). Reference method for broth dilution susceptibility 
testing of yeasts; approved standard. 2nd Edn. CLSI document M27-A2. 
(Wayne, PA: Clinical and Laboratory Standards Institute [CLSI]).
Daood, D., Yiu, C. K. Y., Burrow, M. F., Niu, L.-N., and Tay, F. R. (2017). 
Effect of a novel quaternary ammonium silane on dentin protease activities. 
J. Dent. 58, 19–27. doi: 10.1016/j.jdent.2017.01.001
De Nollin, S., and Borgers, M. (1975). Scanning electron microscopy of Candida 
albicans after in vitro treatment with Miconazole. Antimicrob. Agents Chemother. 
7, 704–711. doi: 10.1128/AAC.7.5.704
Eisenman, H. C., Frases, S., Nicola, A. M., Rodrigues, M. L., and Casadevall, A. 
(2009). Vesicle-associated melanization in Cryptococcus neoformans. 
Microbiology 155, 3860–3867. doi: 10.1099/mic.0.032854-0
Eraso, E., Ruesga, M., Villar-Vidal, M., Carrillo-Muñoz, A. J., Espinel-Ingroff, A., 
and Quindós, G. (2008). Comparative evaluation of ATB fungus 2 and 
Sensititre YeastOne panels for testing in vitro Candida antifungal susceptibility. 
Rev. Iberoam. Micol. 25, 3–6. doi: 10.1016/S1130-1406(08)70002-0
Gong, S. Q., Epasinghe, J., Rueggeberg, F. A., Niu, L. N., Mettenberg, D., 
Yiu, C. K., et al. (2012a). An ORMOSIL-containing orthodontic acrylic 
resin with concomitant improvements in antimicrobial and fracture toughness 
properties. PLoS One 7:e42355. doi: 10.1371/journal.pone.0042355
Gong, S. Q., Huang, Z. B., Shi, W., Ma, B., Tay, F. R., and Zhou, B. (2014). 
In vitro evaluation of antibacterial effect of AH plus incorporated with 
quaternary ammonium epoxy silicate against Enterococcus faecalis. J. Endod. 
40, 1611–1615. doi: 10.1016/j.joen.2014.03.010
Gong, S. Q., Niu, L. N., Kemp, L. K., Yiu, C. K., Ryou, H., Qi, Y. P., et al. 
(2012b). Quaternary ammonium silane-functionalized, methacrylate resin 
composition with antimicrobial activities and self-repair potential. Acta 
Biomater. 8, 3270–3282. doi: 10.1016/j.actbio.2012.05.031
Gould, S. J., and Raposo, G. (2013). As we  wait: coping with an imperfect 
nomenclature for extracellular vesicles. J. Extracell. Vesicles 2. doi: 10.3402/
jev.v2i0.20389
Gulve, N., Kimmerling, K., Johnston, A. D., Krueger, G. R., Ablashi, D. V., 
and Prusty, B. K. (2016). Anti-herpesviral effects of a novel broad range 
anti-microbial quaternary ammonium silane, K21. Antivir. Res. 131, 166–173. 
doi: 10.1016/j.antiviral.2016.05.004
Hao, B., Cheng, S., Clancy, C. J., and Hong Nguyen, M. (2013). Caspofungin 
kills Candida albicans by both cellular amphotericin B apoptosis and necrosis. 
Antimicrob. Agents Chemother. 57, 326–332. doi: 10.1128/AAC.01366-12
Hata, M., Ishii, Y., Watanabe, E., Uoto, K., Kobayashi, S., Yoshida, K., et al. 
(2010). Inhibition of ergosterol synthesis by novel antifungal compounds targeting 
C-14 reductase. Med. Mycol. 48, 613–621. doi: 10.3109/13693780903390208
Hirata, C. H. W. (2015). Oral manifestations in AIDS. Braz. J. Otorhinolaryngol. 
81, 120–123. doi: 10.1016/j.bjorl.2014.12.001
Jennings, M. C., Minbiole, K. P., and Wuest, W. M. (2015). Quarternary 
ammonium compounds: an antimicrobial mainstay and platform for innovation 
to address bacterial resistance. ACS Infect. Dis. 1, 288–303. doi: 10.1021/
acsinfecdis.5b00047
Jiao, Y., Niu, L. N., Ma, S., Li, J., Tay, F. R., and Chen, J. H. (2017). Quaternary 
ammonium-based biomedical materials: state-of-the-art, toxicological aspects 
and antimicrobial resistance. Prog. Polym. Sci. 71, 53–90. doi: 10.1016/j.
progpolymsci.2017.03.001
Johnson, M. D., MacDougall, C., Ostrosky-Zeichner, L., Perfect, J. R., and Rex, 
J. H. (2004). Combination antifungal therapy. Antimicrob. Agents Chemother. 
48, 693–715. doi: 10.1128/AAC.48.3.693-715.2004
Junqueira, J. C., Vilela, S. F., Rossoni, R. D., Barbosa, J. O., Costa, A. C., 
Rasteiro, V. M., et al. (2012). Oral colonization by yeasts in HIV-positive 
patients in Brazil. Rev. Inst. Med. Trop. Sao Paulo 54, 17–24. doi: 10.1590/
S0036-46652012000100004
Kang, K., Fong, W.-P., and Tsang, P. W.-K. (2010). Novel antifungal activity 
of purpurin against Candida species in vitro. Med. Mycol. 48, 904–911. doi: 
10.3109/13693781003739351
Kim, K. S., Kim, Y.-S., Han, I., Kim, M.-H., Jung, M. H., and Park, H.-K. 
(2011). Quantitative and qualitative analysis of the cell death process in 
Candida albicans treated by antifungal agents. PLoS One 6:e28176. doi: 
10.1371/journal.pone.0028176
Klepser, M. E., Ernst, E. J., Lewis, R. E., Ernst, M. E., and Pfaller, M. A. 
(1998). Influence of test conditions on antifungal time-kill curve results: 
proposal for standardized methods. Antimicrob. Agents Chemother. 42, 
1207–1212. doi: 10.1128/AAC.42.5.1207
Kroemer, G., Galluzzi, L., Vandenabeele, P., Abrams, J., Alnemri, E. S., 
Baehrecke, E. H., et al. (2009). Classification of cell death: recommendations 
of the nomenclature committee on cell death 2009. Cell Death Differ. 16, 
3–11. doi: 10.1038/cdd.2008.150
Lee, J., Hwang, J. S., Hwang, I. S., Cho, J., Lee, E., Kim, Y., et al. (2012). 
Coprisin-induced antifungal effects in Candida albicans correlate with apoptotic 
mechanisms. Free Radic. Biol. Med. 52, 2302–2311. doi: 10.1016/j.
freeradbiomed.2012.03.012
Leroy, O., Gangneux, J. P., Montravers, P., Mira, J. P., Gouin, F., Sollet, J. P., 
et al. (2009). Epidemiology, management, and risk factors for death of 
invasive Candida infections in critical care: a multicenter, prospective, 
observational study in France (2005–2006). Crit. Care Med. 37, 1612–1618. 
doi: 10.1097/CCM.0b013e31819efac0
John et al. K21, A Potent Antifungal Agent
Frontiers in Microbiology | www.frontiersin.org 16 May 2019 | Volume 10 | Article 1021
Liu, S., Hou, Y., Chen, X., Gao, Y., Li, H., and Sun, S. (2014). Combination 
of fluconazole with non-antifungal agents: a promising approach to cope 
with resistant Candida albicans infections and insight into new antifungal 
agent discovery. Int. J. Antimicrob. Agents 43, 395–402. doi: 10.1016/j.
ijantimicag.2013.12.009
Liu, X., Li, T., Wang, D., Yang, Y., Sun, W., Liu, J., et al. (2017). Synergistic 
antifungal effect of fluconazole combined with licofelone against 
resistant Candida albicans. Front. Microbiol. 8:2101. doi: 10.3389/
fmicrb.2017.02101
Liu, S., Yue, L., Gu, W., Li, X., Zhang, L., and Sun, S. (2016). Synergistic effect 
of fluconazole and calcium channel blockers against resistant Candida albicans. 
PLoS One 11:e0150859. doi: 10.1371/journal.pone.0150859
Locke, J. B., Almaguer, A. L., Donatelli, J. L., and Bartizal, K. F. (2018). Time-
kill kinetics of rezafungin (CD101) in vagina-simulative medium for 
fluconazole-susceptible and fluconazole-resistant Candida albicans and non-
albicans Candida species. Infect. Dis. Obstet. Gynecol. 2018:7040498. doi: 
10.1155/2018/7040498
Lötvall, J., Hill, A. F., Hochberg, F., Buzás, E. I., Di Vizio, D., Gardiner, C., et al. 
(2014). Minimal experimental requirements for definition of extracellular 
vesicles and their functions: a position statement from the International Society 
for Extracellular Vesicles. J. Extracell. Vesicles 3:26913. doi: 10.3402/jev.v3.26913
Lushniak, B. D. (2014). Antibiotic resistance: a public health crisis. Public 
Health Rep. 129, 314–316. doi: 10.1177/003335491412900402
Mady, O. Y., Donia, A. M., and Al-Madboly, L. A. (2018). Miconazole-urea 
in a Buccal Filmas a new trend for treatment of resistant mouth fungal 
white patches. Front. Microbiol. 9:837. doi: 10.3389/fmicb.2018.00837
Meghil, M. M., Rueggeberg, F., El-Awady, A., Miles, B., Tay, F., Pashley, D., 
et al. (2015). Novel coating of surgical suture confers antimicrobial activity 
against Porphyromonas gingivalis and Enterococcus faecalis. J. Periodontol. 
86, 788–794. doi: 10.1902/jop.2015.140528
Minciacchi, V. R., Freeman, M. R., and Di Vizio, D. (2015). Extracellular 
vesicles in cancer: exosomes, microvesicles and the emerging role of large 
oncosomes. Semin. Cell Dev. Biol. 40, 41–51. doi: 10.1016/j.semcdb.2015.02.010
Mulu, A., Kassu, A., Anagaw, B., Moges, B., Gelaw, A., Alemayehu, M., et al. 
(2013). Frequent detection of ‘azole’ resistant Candida species among late 
presenting AIDS patients in Northwest Ethiopia. BMC Infect. Dis. 13:82. 
doi: 10.1186/1471-2334-13-82
Nosanchuk, J. D., and Casadevall, A. (2003). The contribution of melanin to microbial 
pathogenesis. Cell. Microbiol. 5, 203–223. doi: 10.1046/j.1462-5814.2003.00268.x
Oliveira, D. L., Nakayasu, E. S., Joffe, L. S., Guimarães, A. J., Sobreira, T. J. P., 
Nosanchuk, J. D., et al. (2010). Characterization of yeast extracellular 
vesicles: evidence for the participation of different pathways of cellular 
traffic in vesicle biogenesis. PLoS One 5:e11113. doi: 10.1371/journal.
pone.0011113
Patel, M., Shackleton, J. T., and Coogan, M. M. (2006). Effect of antifungal 
treatment on the prevalence of yeasts in HIV-infected subjects. J. Med. 
Microbiol. 55, 1279–1284. doi: 10.1099/jmm.0.46588-0
Patil, S., Majumdar, B., Sarode, S. C., Sarode, G. S., and Awan, K. H. (2018). 
Oropharyngeal candidosis in HIV-infected patients–an update. Front. Microbiol. 
9:980. doi: 10.3389/fmicb.2018.00980
Peres da Silva, R., Puccia, R., Rodrigues, M. L., Oliveira, D. L., Joffe, L. S., 
César, G. V., et al. (2015). Extracellular vesicle-mediated export of fungal 
RNA. Sci. Rep. 5:7763. doi: 10.1038/srep07763
Pfaller, M. A., Rhomberg, P. R., Messer, S. A., Jones, R. N., and Castanheira, M. 
(2015). Isavuconazole, micafungin, and 8 comparator antifungal agents’ 
susceptibility profiles for common and uncommon opportunistic fungi collected 
in 2013: temporal analysis of antifungal drug resistance using CLSI species-
specific clinical breakpoints and proposed epidemiological cutoff values. Diagn. 
Microbiol. Infect. Dis. 82, 303–313. doi: 10.1016/j.diagmicrobio.2015.04.008
Phillips, A. J., Sudbery, I., and Ramsdale, M. (2003). Apoptosis induced by 
environmental stresses and amphotericin B in Candida albicans. PNAS 100, 
14327–14332. doi: 10.1073/pnas.2332326100
Prasad, R., and Kapoor, K. (2005). Multidrug resistance in the yeast Candida. 
Int. Rev. Cytol. 242, 215–248. doi: 10.1016/S0074-7696(04)42005-1
Prusty, B. K., Niu, L., Kimmerling, K., Johnston, A. D., Tay, F., Krueger, G. R., 
et al. (2014). Novel antiviral compound K21 effective against HSV-1. 3rd 
Antivirals Conference, Amsterdam, Holland.
Read, A. F., and Woods, R. J. (2014). Antibiotic resistance management. Evol. 
Med. Public Health 2014:147. doi: 10.1093/emph/eou024
Rodrigues, M. L., Franzen, A. J., Nimrichter, L., and Miranda, K. (2013). 
Vesicular mechanisms of traffic of fungal molecules to the extracellular 
space. Curr. Opin. Microbiol. 16, 414–420. doi: 10.1016/j.mib.2013.04.002
Rodrigues, M. L., Nimrichter, L., Oliveira, D. L., Nosanchuk, J. D., and Cassevall, A. 
(2008). Vesicular trans-cell wall transport in fungi: a mechanism for the 
delivery of virulence-associated macromolecules? Lipid Insights. 2, 27–40. 
doi: 10.4137/LPI.S1000
Sardi, J. C., Scorzoni, L., Bernardi, T., Fusco-Almeida, A. M., and Mendes 
Giannini, M. J. (2013). Candida species: current epidemiology, pathogenicity, 
biofilm formation, natural antifungal products and new therapeutic options. 
J. Med. Microbiol. 62, 10–24. doi: 10.1099/jmm.0.045054-0
Schwalbe, R., Steele-Moore, L., and Goodwin, A. C. (2007). Antimicrobial 
susceptibility testing protocols. (Boca Raton, FL: CRC Press).
Serpa, R., França, E. J. G., Furlaneto-Maia, L., Andrade, C. G. T. J., Diniz, A., 
and Furlaneto, M. C. (2012). In vitro antifungal activity of the flavonoid 
baicalein against Candida species. J. Med. Microbiol. 61, 1704–1708. doi: 
10.1099/jmm.0.047852-0
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., 
et al. (2018). In vitro and in vivo evaluation of APX001A/APX001 and 
other Gwt1 inhibitors against Cryptococcus. Antimicrob. Agents Chemother. 
62, e00523–e00518. doi: 10.1128/AAC.00523-18
Sholapurkar, A. A., Pai, K. M., and Rao, S. (2009). Comparison of efficacy of 
fluconazole mouthrinse and clotrimazole mouthpaint in the treatment of 
oral candidiasis. Aust. Dent. J. 54, 341–346. doi: 10.1111/j.1834-7819.2009.01160.x
Shrestha, S. K., Grilley, M., Anderson, T., Dhiman, C., Oblad, J., Chang, C. W., 
et al. (2015). In vitro antifungal synergy between amphiphilic aminoglycoside 
K20 and azoles against Candida species and Cryptococcus neoformans. Med. 
Mycol. 53, 837–844. doi: 10.1093/mmy/myv063
Silva, S., Henriques, M., Oliveira, R., Williams, D., and Azeredo, J. (2010). In 
vitro biofilm activity of non-Candida albicans Candida species. Curr. Microbiol. 
61, 534–540. doi: 10.1007/s00284-010-9649-7
Spitzer, M., Robbins, N., and Wright, G. D. (2017). Combinational strategies 
for combating invasive fungal infections. Virulence 8, 169–185. doi: 
10.1080/21505594.2016.1196300
Walker, C. A., Gómez, B. L., Mora-Montes, H. M., Mackenzie, K. S., Munro, C. A., 
Brown, A. J. P., et al. (2010). Melanin externalisation in Candida albicans depends 
on cell wall chitin structures. Eukaryot. Cell 9, 1329–1342. doi: 10.1128/EC.00051-10
Wang, C., and Youle, R. J. (2009). The role of mitochondria in apoptosis. 
Annu. Rev. Genet. 43, 95–118. doi: 10.1146/annurev-genet-102108-134850
Weerasinghe, P., and Buja, L. M. (2012). Oncosis: an important non-apoptotic 
mode of cell death. Exp. Mol. Pathol. 93, 302–308. doi: 10.1016/j.yexmp.2012.09.018
Witaningrum, A. M., Khairunisa, S. Q., Yunifiar, M. Q., Bramanthi, R., and 
Rachman, B. E. (2018). Opportunistic infection of HIV/AIDS patients in 
West Papua. IOP Conf. Ser. Earth Environ. Sci. 125:012062. doi: 
10.1088/1755-1315/125/1/012062
Wolf, J. M., Espadas-Moreno, J., Luque-Garcia, J. L., and Casadevall, A. (2014). 
Interaction of Cryptococcus neoformans extracellular vesicles with the cell 
wall. Eukaryot. Cell 13, 1484–1493. doi: 10.1128/EC.00111-14
Wong, S. S., Kao, R. Y., Yuen, K. Y., Wang, Y., Yang, D., Samaranayake, L. P., 
et al. (2014). In vitro and in vivo activity of a novel antifungal small molecule 
against Candida infections. PLoS One 9:e85836. doi: 10.1371/journal.
pone.0085836
Zusman, O., Avni, T., Leibovici, L., Adler, A., Friberg, L., Stergiopoulou, T., 
et al. (2013). Systematic review and meta-analysis of in  vitro synergy of 
polymyxins and carbapenems. Antimicrob. Agents Chemother. 57, 5104–5111. 
doi: 10.1128/AAC.01230-13
Conflict of Interest Statement: The authors declare that the research was 
conducted in the absence of any commercial or financial relationships that could 
be  construed as a potential conflict of interest except for a grant from fiteBac 
Technology which covered a PhD bursary for CJ. All other authors declare no 
competing interests.
Copyright © 2019 John, Abrantes, Prusty, Ablashi and Africa. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) and the copyright owner(s) are credited and that the original publication 
in this journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
